FDA
-
-
-
-
-
-
-
UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook
-
-
-
-
-
-
-
Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's
-
-
-
-
-
-
-
FDA: 'The agency today is withdrawing final guidance titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product'
-
-
-
-
-
-
-
Teva Pharma (TEVA) Gets FDA Ok For aNDA For Ferric Citrate Anhydrous
-
-
-
-
-
-
-
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
-
-
-
-
-
-
-
FDA approves UZEDY for bipolar I disorder maintenance treatment
-
-
-
-
-
-
-
Alvotech (ALVO) and Teva (TEVA) Announce FDA Approval of Interchangeability for SELARSDI with Stelara
-
330,173 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

